The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review
Background: Irritable bowel syndrome (IBS) is a common gastrointestinal tract disorder, affecting 10–20% of adults worldwide. Mebeverine is an antispasmodic agent indicated for the symptomatic treatment of abdominal pain caused by intestinal smooth muscle spasms and intestinal functional disorders i...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/4/1044 |
| _version_ | 1797479120553115648 |
|---|---|
| author | Jaroslaw Daniluk Ewa Malecka-Wojciesko Barbara Skrzydlo-Radomanska Grazyna Rydzewska |
| author_facet | Jaroslaw Daniluk Ewa Malecka-Wojciesko Barbara Skrzydlo-Radomanska Grazyna Rydzewska |
| author_sort | Jaroslaw Daniluk |
| collection | DOAJ |
| description | Background: Irritable bowel syndrome (IBS) is a common gastrointestinal tract disorder, affecting 10–20% of adults worldwide. Mebeverine is an antispasmodic agent indicated for the symptomatic treatment of abdominal pain caused by intestinal smooth muscle spasms and intestinal functional disorders in the course of IBS. The aim of this article was to perform a systematic literature review and update previous overviews of the efficacy and safety of mebeverine treatment in IBS. Methods: Major electronic medical databases, PubMed, EMBASE and Cochrane, were systematically searched from January 1965 to January 2021. Results: Twenty-two studies met our inclusion criteria, including 19 randomised trials, two observational retrospective studies, and one non-randomised, single-blinded study. Six studies reported a significant decrease in abdominal pain after mebeverine treatment (<i>p</i>-values ranging from <0.05 to <0.001). Only three studies showed no improvement after mebeverine treatment in terms of the severity of abdominal pain or discomfort. Some of the included studies also showed significant improvements in abnormal bowel habits, abdominal distension, as well as stool frequency and consistency. Adverse events were rare and associated mainly with IBS symptoms. Conclusions: Mebeverine is an effective treatment option in IBS, with a good safety profile and low frequency of adverse effects. |
| first_indexed | 2024-03-09T21:41:08Z |
| format | Article |
| id | doaj.art-81385e997fba47f78711d7395c8ebd01 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T21:41:08Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-81385e997fba47f78711d7395c8ebd012023-11-23T20:30:47ZengMDPI AGJournal of Clinical Medicine2077-03832022-02-01114104410.3390/jcm11041044The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic ReviewJaroslaw Daniluk0Ewa Malecka-Wojciesko1Barbara Skrzydlo-Radomanska2Grazyna Rydzewska3Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, PolandDepartment of Digestive Tract Diseases, Medical University of Lodz, 90-153 Lodz, PolandDepartment of Gastroenterology with Endoscopy Laboratory, Medical University of Lublin, 20-090 Lublin, PolandClinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit, CSK MSWiA, 02-507 Warsaw, PolandBackground: Irritable bowel syndrome (IBS) is a common gastrointestinal tract disorder, affecting 10–20% of adults worldwide. Mebeverine is an antispasmodic agent indicated for the symptomatic treatment of abdominal pain caused by intestinal smooth muscle spasms and intestinal functional disorders in the course of IBS. The aim of this article was to perform a systematic literature review and update previous overviews of the efficacy and safety of mebeverine treatment in IBS. Methods: Major electronic medical databases, PubMed, EMBASE and Cochrane, were systematically searched from January 1965 to January 2021. Results: Twenty-two studies met our inclusion criteria, including 19 randomised trials, two observational retrospective studies, and one non-randomised, single-blinded study. Six studies reported a significant decrease in abdominal pain after mebeverine treatment (<i>p</i>-values ranging from <0.05 to <0.001). Only three studies showed no improvement after mebeverine treatment in terms of the severity of abdominal pain or discomfort. Some of the included studies also showed significant improvements in abnormal bowel habits, abdominal distension, as well as stool frequency and consistency. Adverse events were rare and associated mainly with IBS symptoms. Conclusions: Mebeverine is an effective treatment option in IBS, with a good safety profile and low frequency of adverse effects.https://www.mdpi.com/2077-0383/11/4/1044irritable bowel syndromemebeverinesystematic review |
| spellingShingle | Jaroslaw Daniluk Ewa Malecka-Wojciesko Barbara Skrzydlo-Radomanska Grazyna Rydzewska The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review Journal of Clinical Medicine irritable bowel syndrome mebeverine systematic review |
| title | The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review |
| title_full | The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review |
| title_fullStr | The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review |
| title_full_unstemmed | The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review |
| title_short | The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review |
| title_sort | efficacy of mebeverine in the treatment of irritable bowel syndrome a systematic review |
| topic | irritable bowel syndrome mebeverine systematic review |
| url | https://www.mdpi.com/2077-0383/11/4/1044 |
| work_keys_str_mv | AT jaroslawdaniluk theefficacyofmebeverineinthetreatmentofirritablebowelsyndromeasystematicreview AT ewamaleckawojciesko theefficacyofmebeverineinthetreatmentofirritablebowelsyndromeasystematicreview AT barbaraskrzydloradomanska theefficacyofmebeverineinthetreatmentofirritablebowelsyndromeasystematicreview AT grazynarydzewska theefficacyofmebeverineinthetreatmentofirritablebowelsyndromeasystematicreview AT jaroslawdaniluk efficacyofmebeverineinthetreatmentofirritablebowelsyndromeasystematicreview AT ewamaleckawojciesko efficacyofmebeverineinthetreatmentofirritablebowelsyndromeasystematicreview AT barbaraskrzydloradomanska efficacyofmebeverineinthetreatmentofirritablebowelsyndromeasystematicreview AT grazynarydzewska efficacyofmebeverineinthetreatmentofirritablebowelsyndromeasystematicreview |